Rankings
▼
Calendar
SYRE (Spyre Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
SYRE
Spyre Therapeutics, Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$90M
Net Income (TTM)
-$155M
EPS (TTM)
-$1.57
Free Cash Flow (TTM)
-$169M
Gross Margin
0.0%
Op. Margin
-231.6%
Net Margin
-171.5%
FCF Margin
-187.0%
P/S Ratio (TTM)
28.4x
P/E Ratio (TTM)
—
YoY Rev Growth
—
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$198K
-$350K
-$19M
Q2 23
$688K
$688K
-$159M
Q3 23
$0
$0
-$18M
Q4 23
$0
$0
-$46M
Q1 24
$0
$0
-$48M
Q2 24
$0
$0
-$44M
Q3 24
$0
$0
-$55M
Q4 24
$0
$0
-$61M
Q1 25
$0
$0
-$54M
Q2 25
$0
$0
-$42M
Q3 25
$0
-$45M
-$57M
Q4 25
$90M
$45M
-$57M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
2209.0x
—
Q2 23
2095.7x
—
Q3 23
2441.7x
—
Q4 23
2904.7x
—
Q1 24
3740.6x
—
Q2 24
—
—
Q3 24
—
—
Q4 24
—
—
Q1 25
—
—
Q2 25
—
—
Q3 25
—
—
Q4 25
28.4x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$18M
-$18M
Q2 23
-$17M
-$17M
Q3 23
-$35M
-$35M
Q4 23
-$31M
-$31M
Q1 24
-$29M
-$29M
Q2 24
-$62M
-$62M
Q3 24
-$29M
-$29M
Q4 24
-$37M
-$37M
Q1 25
-$41M
-$41M
Q2 25
-$47M
-$47M
Q3 25
-$37M
-$37M
Q4 25
-$45M
-$45M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$0
Q2 23
$0
Q3 23
$0
Q4 23
$0
Q1 24
$0
Q2 24
$0
Q3 24
$0
Q4 24
$0
Q1 25
$0
Q2 25
$0
Q3 25
$0
Q4 25
$0
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-85.5%
-26.3%
Q2 23
+10.1%
+593.9%
Q3 23
-100.0%
-3.1%
Q4 23
-100.0%
+137.5%
Q1 24
-100.0%
+151.4%
Q2 24
-100.0%
-72.4%
Q3 24
—
+202.1%
Q4 24
—
+33.4%
Q1 25
—
+12.1%
Q2 25
—
-5.0%
Q3 25
—
+2.7%
Q4 25
—
+141.1%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$2M
863.1%
Q2 23
$2M
277.8%
Q3 23
$5M
—
Q4 23
$17M
—
Q1 24
$14M
—
Q2 24
$9M
—
Q3 24
$13M
—
Q4 24
$9M
—
Q1 25
$9M
—
Q2 25
$9M
—
Q3 25
$10M
—
Q4 25
$10M
10.8%
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$14M
—
$5M
Q2 23
$17M
$12M
—
Q3 23
$25M
$9M
—
Q4 23
$34M
$14M
—
Q1 24
$35M
$13M
—
Q2 24
$33M
$12M
—
Q3 24
$45M
$11M
—
Q4 24
$50M
$11M
—
Q1 25
$42M
$12M
—
Q2 25
$40M
$12M
—
Q3 25
$45M
$12M
—
Q4 25
$45M
$13M
—
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$35M
$3M
$38M
Q2 23
$235M
$0
$235M
Q3 23
$91M
$113M
$204M
Q4 23
$189M
$150M
$339M
Q1 24
$228M
$257M
$485M
Q2 24
$45M
$381M
$426M
Q3 24
$72M
$343M
$414M
Q4 24
$89M
$514M
$603M
Q1 25
$48M
$516M
$565M
Q2 25
$82M
$445M
$527M
Q3 25
$65M
$421M
$486M
Q4 25
$86M
$671M
$757M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
4M
+44.2%
Q2 23
4M
+1.4%
Q3 23
4M
+12.3%
Q4 23
22M
+405.5%
Q1 24
37M
+68.2%
Q2 24
45M
+24.1%
Q3 24
51M
+12.3%
Q4 24
47M
-7.6%
Q1 25
60M
+28.2%
Q2 25
61M
+0.7%
Q3 25
60M
-0.5%
Q4 25
346M
+472.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
$154K
30
FY 17
$121K
43
FY 18
$64K
61
FY 19
$0
76
FY 20
$0
90
FY 21
$186K
101
FY 22
$34K
69
FY 23
$30K
30
FY 24
$0
65
FY 25
$0
102
marketcaparena.com